Literature DB >> 20816038

Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers.

James A Bourgeois1, Andreea L Seritan, E Melina Casillas, David Hessl, Andrea Schneider, Ying Yang, Inderjeet Kaur, Jennifer B Cogswell, Danh V Nguyen, Randi J Hagerman.   

Abstract

OBJECTIVE: The authors studied the lifetime prevalence of DSM-IV-TR psychiatric disorders in a population of adults with the fragile X premutation.
METHOD: The Structured Clinical Interview for DSM-IV was conducted, from 2007-2008, in 85 individuals with the fragile X premutation, 47 with the fragile X-associated tremor/ataxia syndrome (FXTAS; 33 male, 14 female; mean age = 66 years) and 38 without FXTAS (16 male, 22 female; mean age = 52 years). Lifetime prevalence for mood and anxiety disorders among carriers with and without FXTAS was compared to available age-specific population estimates from the National Comorbidity Survey Replication (NCS-R).
RESULTS: Among participants with FXTAS, 30 (65%) met lifetime DSM-IV-TR criteria for a mood disorder; 24 (52%) met lifetime DSM-IV-TR criteria for an anxiety disorder. Among the non-FXTAS participants, there were 15 instances of lifetime mood disorder (42%) and 18 of lifetime anxiety disorder (47%). When compared to age-specific NCS-R data, the lifetime prevalences of any mood disorder (P < .0001), major depressive disorder (P < .0001), any anxiety disorder (P < .0001), panic disorder (P = .006), specific phobia (P = .0003), and posttraumatic stress disorder (P = .004) were significantly higher in participants with FXTAS. The lifetime rates of social phobia in individuals with the premutation without FXTAS were significantly higher than NCS-R data (P = .001).
CONCLUSIONS: This sample of carriers of the fragile X premutation had a notably high lifetime risk of mood and anxiety disorders. Mood and anxiety disorders may be part of the clinical phenotype of the fragile X premutation conditions, especially in carriers with FXTAS. Clinicians encountering these patients are advised to consider FXTAS as a neuropsychiatric syndrome as well as a neurologic disorder. © Copyright 2011 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20816038      PMCID: PMC4038118          DOI: 10.4088/JCP.09m05407blu

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  66 in total

1.  Fragile X-associated tremor/ataxia syndrome--an older face of the fragile X gene.

Authors:  Paul J Hagerman; Randi J Hagerman
Journal:  Nat Clin Pract Neurol       Date:  2007-02

2.  Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation.

Authors:  Faraz Farzin; Hazel Perry; David Hessl; Danuta Loesch; Jonathan Cohen; Susan Bacalman; Louise Gane; Flora Tassone; Paul Hagerman; Randi Hagerman
Journal:  J Dev Behav Pediatr       Date:  2006-04       Impact factor: 2.225

3.  Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation.

Authors:  David Hessl; Flora Tassone; Danuta Z Loesch; Elizabeth Berry-Kravis; Maureen A Leehey; Louise W Gane; Ingrid Barbato; Cathlin Rice; Emma Gould; Deborah A Hall; James Grigsby; Jacob A Wegelin; Susan Harris; Foster Lewin; Dahlia Weinberg; Paul J Hagerman; Randi J Hagerman
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2005-11-05       Impact factor: 3.568

4.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

5.  Concordance of the Composite International Diagnostic Interview Version 3.0 (CIDI 3.0) with standardized clinical assessments in the WHO World Mental Health surveys.

Authors:  Josep Maria Haro; Saena Arbabzadeh-Bouchez; Traolach S Brugha; Giovanni de Girolamo; Margaret E Guyer; Robert Jin; Jean Pierre Lepine; Fausto Mazzi; Blanca Reneses; Gemma Vilagut; Nancy A Sampson; Ronald C Kessler
Journal:  Int J Methods Psychiatr Res       Date:  2006       Impact factor: 4.035

6.  Association of FMR1 repeat size with ovarian dysfunction.

Authors:  A K Sullivan; M Marcus; M P Epstein; E G Allen; A E Anido; J J Paquin; M Yadav-Shah; S L Sherman
Journal:  Hum Reprod       Date:  2004-12-17       Impact factor: 6.918

Review 7.  The fragile-X premutation: a maturing perspective.

Authors:  Paul J Hagerman; Randi J Hagerman
Journal:  Am J Hum Genet       Date:  2004-03-29       Impact factor: 11.025

Review 8.  Lessons from fragile X regarding neurobiology, autism, and neurodegeneration.

Authors:  Randi J Hagerman
Journal:  J Dev Behav Pediatr       Date:  2006-02       Impact factor: 2.225

9.  Reduced Hippocampal Activation During Recall is Associated with Elevated FMR1 mRNA and Psychiatric Symptoms in Men with the Fragile X Premutation.

Authors:  Kami Koldewyn; David Hessl; John Adams; Flora Tassone; Paul J Hagerman; Randi J Hagerman; Susan M Rivera
Journal:  Brain Imaging Behav       Date:  2008-01-18       Impact factor: 3.978

10.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

View more
  103 in total

1.  Daily health symptoms of mothers of adolescents and adults with fragile x syndrome and mothers of adolescents and adults with autism spectrum disorder.

Authors:  Leann E Smith; Marsha Mailick Seltzer; Jan S Greenberg
Journal:  J Autism Dev Disord       Date:  2012-09

2.  Immune mediated disorders in women with a fragile X expansion and FXTAS.

Authors:  Isha Jalnapurkar; Nuva Rafika; Flora Tassone; Randi Hagerman
Journal:  Am J Med Genet A       Date:  2014-11-14       Impact factor: 2.802

3.  Sleep apnea in fragile X premutation carriers with and without FXTAS.

Authors:  Alyssa Hamlin; Ying Liu; Danh V Nguyen; Flora Tassone; Lin Zhang; Randi J Hagerman
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2011-09-19       Impact factor: 3.568

4.  Identification of expanded alleles of the FMR1 gene among high-risk population in Indonesia by using blood spot screening.

Authors:  Tri Indah Winarni; Agustini Utari; Farmaditya E P Mundhofir; Tzuhan Tong; Blythe Durbin-Johnson; Sultana M H Faradz; Flora Tassone
Journal:  Genet Test Mol Biomarkers       Date:  2011-10-11

Review 5.  Fragile X: leading the way for targeted treatments in autism.

Authors:  Lulu W Wang; Elizabeth Berry-Kravis; Randi J Hagerman
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 6.  Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder.

Authors:  Reymundo Lozano; Veronica Martinez-Cerdeno; Randi J Hagerman
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

7.  Mouse models of the fragile x premutation and the fragile X associated tremor/ataxia syndrome.

Authors:  Michael R Hunsaker; Gloria Arque; Robert F Berman; Rob Willemsen; Renate K Hukema
Journal:  Results Probl Cell Differ       Date:  2012

8.  Eye movements reveal impaired inhibitory control in adult male fragile X premutation carriers asymptomatic for FXTAS.

Authors:  Ling M Wong; Naomi J Goodrich-Hunsaker; Yingratana McLennan; Flora Tassone; Melody Zhang; Susan M Rivera; Tony J Simon
Journal:  Neuropsychology       Date:  2014-04-28       Impact factor: 3.295

9.  Characterization and Early Detection of Balance Deficits in Fragile X Premutation Carriers With and Without Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS).

Authors:  Joan A O'Keefe; Erin Robertson-Dick; Emily J Dunn; Yan Li; Youping Deng; Amber N Fiutko; Elizabeth Berry-Kravis; Deborah A Hall
Journal:  Cerebellum       Date:  2015-12       Impact factor: 3.847

10.  Immune-mediated disorders among women carriers of fragile X premutation alleles.

Authors:  Tri Indah Winarni; Weerasak Chonchaiya; Tanjung Ayu Sumekar; Paul Ashwood; Guadalupe Mendoza Morales; Flora Tassone; Danh V Nguyen; Sultana M H Faradz; Judy Van de Water; Kylee Cook; Alyssa Hamlin; Yi Mu; Paul J Hagerman; Randi J Hagerman
Journal:  Am J Med Genet A       Date:  2012-08-17       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.